The following CONARIS drug candidates have reached application in humans:



OlamkiceptDrug candidate: IL-6 trans-signalling inhibitor (out-licensed to Ferring Pharmaceuticals)
CR12/01Drug candidate: gut microbiota modulator (small molecule)
CR12/02Drug candidate: gut microbiota modulator (small molecule)
CR13/01Drug candidate: intestinal microenvironment transfer / fecal filtrate transfer (sold in 2017)
CR15/01Diagnostic product candidate for colonoscopy (out-licensed in 2018)

18 September, 2020